Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.
Elevated plasma plasminogen activator inhibitor-1 (PAI-1) level is a core feature of insulin-resistance syndrome (IRS). Atherothrombotic complications in IRS are partly attributed to impaired fibrinolysis caused by increased plasma PAI-1 levels. Although the etiology of IRS is far from being explained, the clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link. Proinflammatory cytokines might regulate PAI-1 expression in IRS; however, more studies are needed to confirm this complex mechanism in humans. Furthermore, modifying PAI-1 expression by PAI-1 inhibitors provides a new challenge and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.
Juhan-Vague
I
I
Laboratory of Hematology, CHU Timone, Inserm Epi 99-36, Marseille, France. ijuhan@ap-hm.fr
Alessi
M-C
MC
Mavri
A
A
Morange
P E
PE
D000818:Animals; D006331:Heart Diseases / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D009765:Obesity / Q000378:metabolism*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism* / Q000502:physiology*; D012306:Risk
D017395:Plasminogen Activator Inhibitor 1